VIRALEZE™ Antiviral Nasal Spray

 

assets/uploads/2021-04/Viraleze_double_carton_onebottle_cropped

What is VIRALEZE™ Antiviral Nasal Spray?

VIRALEZE™ is an antiviral nasal spray that contains astodrimer sodium (SPL7013), which has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2, the virus that causes COVID-19.^

^Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Available at SSRN: https://ssrn.com/abstract=3830085

 

VIRALEZE™ was developed in Australia by Starpharma, a world leader in the development of new medical products based on its proprietary dendrimer technology.

The active in VIRALEZE™, astodrimer sodium (also known as SPL7013), is a patented, precisely designed large molecule that cannot pass into the bloodstream and that acts locally at site of application in the nasal cavity.

Astodrimer sodium is included in products approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand. 

VIRALEZE™ is complimentary to other measures such as vaccines, masks, and physical distancing.

VIRALEZE™ is registered for sale in the UK/Europe. VIRALEZE™ launched in the UK through LloydsPharmacy, as announced on 25 March 2021 and then in Europe via Starpharma's www.viraleze.co webstore, as announced on 6 May 2021. Starpharma is also progressing regulatory activities for a number of markets, including Australia, with the intention of rolling it out across other markets.

Starpharma was awarded development funding for VIRALEZE™ by the Australian Government’s Medical Research Future Fund Biomedical Translation Bridge Program. 

 

How does VIRALEZE™ work?

 

VIRALEZE™ targets the area in the nasal cavity where respiratory viruses that cause colds, flu and more severe respiratory illness, such as COVID-19, first attach and start to multiply. The nasal cavity is the primary site where SARS-CoV-2 (COVID-19) becomes established, before spreading to the lungs.^

VIRALEZE™ contains astodrimer sodium (SPL7013) which is antiviral and has been shown in laboratory studies to inactivate viruses, adding a further physical barrier to respiratory viruses. 

Viraleze_animation

click here to play video.

^Hou, Y.J., et al. 2020. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182(2), 429-446.e14. https://doi.org/10.1016/j.cell.2020.05.042
† Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Available at SSRN: https://ssrn.com/abstract=3830085

 

Astodrimer sodium (SPL7013) acts by blocking the interaction between the
SARS-CoV-2 viral “spikes” and the human cells the virus is seeking to infect.

Viraleze MoA

“Spike” proteins on the surface of these (SARS-CoV-2) viruses that come into contact with VIRALEZE™ are trapped by astodrimer sodium. This interaction is “virucidal” – the virus is irreversibly blocked and can no longer infect cells.

This mechanism provides a physical barrier to respiratory viruses in the nasal cavity. The “blocked” viruses are then cleared naturally through the nasal mucus.

† Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Available at SSRN: https://ssrn.com/abstract=3830085

For more information: 

Download ASX Announcement: VIRALEZE™ launches in Europe (PDF 218kb) - 6 May 2021

Download ASX Announcement: VIRALEZE™ now launched by LloydsPharmacy in the UK (PDF 224kb) - 30 March 2021

Download ASX Announcement: VIRALEZE™ to be launched with LloydsPharmacy in the UK (PDF 241kb) - 25 March 2021

Download ASX Announcement: SPL7013 active against other pandemic coronaviruses (PDF 418kb) - 3 March 2021

Download ASX Announcement: VIRALEZE™ antiviral nasal spray registered in Europe (PDF 226kb) - 23 February 2021

Download full announcement: VIRALEZE COVID-19 nasal spray study to commence in January (PDF 71kb) - 22 December 2020

Download full announcement: VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21 (PDF 113kb) – 10 December 2020

Download full announcement: SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray (PDF 95kb) – 19 November 2020

Download full announcement: SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2 (PDF 183kb) – 14 September 2020

Download full announcement: SPL7013 nasal spray for COVID-19 – development update (PDF 267kb) – 25 August 2020

Download ASX Announcement: SPL7013 shows significant activity against SARS-CoV-2 (coronavirus) (pdf file, 69kb) – 15 April 2020